Lowers the risk of stroke and systemic embolism. ANDA 208067, held by Mylan. Dabigatran Etexilate Mesylate.
As of Nov 16, 2026, ANDA 208067 (Dabigatran Etexilate Mesylate), held by Mylan, was first approved by FDA on Feb 3, 2025, with 0 approved supplements and 0 published complete response letters.
Dabigatran etexilate capsules are a direct thrombin inhibitor indicated:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 3, 2025 | Original application | Approved |
| Dabigatran Etexilate MesylateEQ 75MG BASE · capsule;oral | Dabigatran Etexilate Mesylate | Rx |
| Dabigatran Etexilate MesylateEQ 150MG BASE · capsule;oral | Dabigatran Etexilate Mesylate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters